Cass, L M <br/><br/>
The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers.  [electronic resource] 

 -  Journal of clinical pharmacology  May 2001 
 - 528-35 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0091-2700 
<br/><br/><label>Standard No.: </label>10.1177/00912700122010401  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Area Under Curve<br/>Biological Availability<br/>Confidence Intervals<br/>Cross-Over Studies<br/>Dietary Fats<br/>Food-Drug Interactions<br/>Gastrointestinal Diseases--chemically induced<br/>Half-Life<br/>Headache--chemically induced<br/>Humans<br/>Least-Squares Analysis<br/>Male<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Quinoxalines--adverse effects<br/>Reverse Transcriptase Inhibitors--adverse effects